Treatment-Resistant Hypertension Market: Latest Study by DelveInsight Reveals a Lucrative Investment Opportunity and Growth Prospect | Idorsia, Janssen, CinCor Pharma, Ionis, Vifor Pharma

November 30 11:38 2023
Treatment-Resistant Hypertension Market: Latest Study by DelveInsight Reveals a Lucrative Investment Opportunity and Growth Prospect | Idorsia, Janssen, CinCor Pharma, Ionis, Vifor Pharma
Delveinsight Business Research LLP
DelveInsight’s “Treatment-Resistant Hypertension Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Treatment-Resistant Hypertension market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The report covers emerging Treatment-Resistant Hypertension drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Treatment-Resistant Hypertension treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Treatment-Resistant Hypertension: An Overview

Hypertension (HTN) is a clinical condition in which the blood vessels have a persistently raised pressure. According to the World Health Organization, an estimated 1.28 billion adults aged 30–79 years worldwide have HTN. HTN significantly increases the risks of heart, brain, kidney, and other diseases. 

Resistant hypertension (RHTN) is defined as uncontrolled blood pressure, despite the use of ≥3 antihypertensive agents of different classes, including a diuretic, usually thiazide-like, a long-acting calcium channel blocker, and a blocker of the renin–angiotensin system, either an ACE (angiotensin-converting enzyme) inhibitor or an ARB (angiotensin receptor blocker), at maximal or maximally tolerated doses.

The estimated prevalence of RHTN among treated HTN patients is approximately 10–13%. RHTN is associated with older age, black race, left ventricular hypertrophy, chronic kidney disease, obesity, and diabetes. It affects females more than males.

Treatment-Resistant Hypertension Market Key Facts

  • Treatment-resistant Hypertension market size in the seven major markets was USD 13 billion in 2021. As per DelveInsight, the Treatment-Resistant Hypertension Market is anticipated to evolve immensely in the coming years owing to the rise in the number of cases, the launch of new therapies, and the active participation of the pharma and biotech companies such as Quantum Genomics, Idorsia Pharmaceuticals, CinCor Pharma, Ionis Pharmaceuticals, Vifor Pharma, among others in the therapeutic domain.

  • The total Treatment-Resistant Hypertension prevalent cases of in 7MM countries was ~16.4 million in 2021.

  • According to DelveInsight’s analysis, RHTN is more prevalent in females as compared to males. DelveInsight’s epidemiology model for RHTN estimates that in the US, ~44% of cases were males, and ~55% were females in 2020.

  • Among EU5 countries, Germany had the highest number of prevalent cases of treatment-resistant hypertension (1,400,926 cases) in 2021.

  • The UK had the lowest prevalent population of treatment-resistant hypertension (598,163 cases) in 2021.

Treatment-Resistant Hypertension Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Treatment-Resistant Hypertension pipeline therapies. It also thoroughly assesses the Treatment-Resistant Hypertension market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete details of the market trend for each marketed Treatment-Resistant Hypertension drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.

Treatment-Resistant Hypertension Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted Treatment-Resistant Hypertension epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Treatment-Resistant Hypertension epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders. 

The Report Covers the Treatment-Resistant Hypertension Epidemiology, Segmented as –

  • Total Prevalent Cases of Treatment-resistant Hypertension [2019–2032]

  • Age-specific Cases of Treatment-resistant Hypertension [2019–2032]

  • Gender-specific Cases of Treatment-resistant Hypertension [2019–2032]

Treatment-Resistant Hypertension Drugs Uptake and Pipeline Development Activities

The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Treatment-Resistant Hypertension market or expected to be launched during the study period. The analysis covers the Treatment-Resistant Hypertension market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares Treatment-Resistant Hypertension drugs based on their sale and market share.

The report also covers the Treatment-Resistant Hypertension pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Treatment-Resistant Hypertension companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How the Treatment-Resistant Hypertension Market Will Evolve and Grow by 2032 @

Treatment-Resistant Hypertension Therapeutics Market Outlook

Pharmacologic treatment options include switching, combination, and potentiation strategies among commonly used antidepressant drugs. Most of the available antidepressants, such as selective serotonin reuptake inhibitors (SSRI), dual serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants, irreversible, non-selective monoamine oxidase inhibitors (MAOIs), α2-antagonists, agomelatine, tianeptine are used to treat TRD.

Various non-pharmacological therapies are also recommended that including electroconvulsive therapy (ECT), repetitive transcranial magnetic stimulation (rTMS), and vagus nerve stimulation (VNS). Along with this, two alternative forms of psychotherapy involve majorly cognitive-behavioral therapy (CBT) and interpersonal therapy (IPT). 

Unmet needs like the lack of universal diagnostic criteria for “TRD,” lack of real-time TRD epidemiological studies, and the ready availability of traditional antidepressant generics hamper the market’s growth. Further due to the increasing prevalence of depression, the treatment rate of mental illness, and resistance to available drugs is increasing. There is a need for more effective treatments.

The pipeline for TRD includes MK-1942 (Merck/Novamind), COMP360 psilocybin therapy (COMPASS Pathways), MIJ821 (Novartis), NV-5138 (Navitor Pharmaceuticals/Supernus Pharmaceuticals), and DB104 (Denovo Biopharma), and others. Due to a robust pipeline equipped with high-priced therapies on one side and a dynamic market space with increasing pressure from payers and limitations in evidence development on the other, market access strategies become all the more important for a successful market launch in TRD.

The US FDA-approved therapies for TRD include Eli Lilly’s SYMBYAX, an olanzapine and fluoxetine combination, approved in 2009 for the acute treatment of TRD, and Johnson & Johnson’s SPRAVATO, an intranasal esketamine, approved in 2019, for use in conjunction with an oral antidepressant in adults with TRD.

Treatment-Resistant Hypertension Companies Actively Working in the Therapeutics Market Include

  • Idorsia Ltd

  • Janssen Biotech

  • Quantum Genomics SA

  • CinCor Pharma

  • Ionis Pharmaceuticals

  • Vifor Pharma

  • KBP Biosciences

And Many Others

Emerging and Marketed Treatment-Resistant Hypertension Therapies Covered in the Report Include:

  • Aprocitentan: Idorsia Ltd/Janssen Biotech

  • Firibastat (QGC001): Quantum Genomics SA

  • CIN-107: CinCor Pharma

  • Firibastat: Quantum Genomics

  • Aprocitentan: Idorsia Pharmaceuticals

  • CIN-107: CinCor Pharma

  • IONIS-AGT-LRx: Ionis Pharmaceuticals

  • Patiromer: Vifor Pharma

And Many More

The Report Covers an In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Treatment-Resistant Hypertension Competitive Intelligence Analysis

4. Treatment-Resistant Hypertension Market Overview at a Glance

5. Treatment-Resistant Hypertension Disease Background and Overview

6. Treatment-Resistant Hypertension Patient Journey

7. Treatment-Resistant Hypertension Patient Population and Epidemiology Trends (In the US, EU5, and Japan)

8. Treatment-Resistant Hypertension Treatment Algorithm, Current Treatment, and Medical Practices

9. Treatment-Resistant Hypertension Unmet Needs

10. Key Endpoints of Treatment-Resistant Hypertension Treatment

11. Treatment-Resistant Hypertension Marketed Therapies

12. Treatment-Resistant Hypertension Emerging Drugs and Latest Therapeutic Advances

13. Treatment-Resistant Hypertension Seven Major Market Analysis

14. Attribute Analysis

15. Treatment-Resistant Hypertension Market Outlook (In US, EU5, and Japan)

16. Treatment-Resistant Hypertension Companies Active in the Market

17. Treatment-Resistant Hypertension Access and Reimbursement Overview

18. KOL Views on the Treatment-Resistant Hypertension Market

19. Treatment-Resistant Hypertension Market Drivers

20. Treatment-Resistant Hypertension Market Barriers

21. Appendix

22. DelveInsight Capabilities

23. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download the Sample PDF to Learn More About the Key Offerings of the Report @



About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Other Trending Healthcare Reports by DelveInsight

Aneurysmal Subarachnoid Hemorrhage (SAH) Market

“Aneurysmal Subarachnoid Hemorrhage Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Aneurysmal Subarachnoid Hemorrhage market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Aneurysmal Subarachnoid Hemorrhage market.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States